LBBW Bonus Zert BAYN 24.04.2026/ DE000LB3QZ24 /
2024-11-12 3:54:27 PM | Chg.-2.80 | Bid8:00:00 PM | Ask8:00:00 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
21.19EUR | -11.67% | - Bid Size: - |
- Ask Size: - |
BAYER AG NA O.N. | - - | 2026-04-24 | Call |
GlobeNewswire
08-02
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...
GlobeNewswire
07-11
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...
GlobeNewswire
05-30
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire
05-30
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
05-28
Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement
GlobeNewswire
05-02
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire
04-18
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire
04-16
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire
04-11
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire
03-25
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire
03-06
BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...